Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549	
------------------------	--

STATEMENT OF CHANGES IN BENEFICIAL OWNE	RSHIP

OMB APPROVAL										
OMB Number: 3235-028										
Estimated average burden										
hours per response:	0.5									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Pare Anthony					2. Issuer Name and Ticker or Trading Symbol T2 Biosystems, Inc. [ TTOO ]								(Checl	all app Direc	tor	ng Pe	erson(s) to Is 10% O Other (	wner	
(Last) (First) (Middle) 101 HARTWELL AVENUE						3. Date of Earliest Transaction (Month/Day/Year) 03/17/2021								X	below	Officer (give title below)  Chief Comm		below)	specify
(Street) LEXING (City)			2421 Zip)		4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Indi Line) X	Form Form	fual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day					ion 2A. Deemed Execution Date,			3.			A) or 5. Am Securible Bene Owner		cially Following	Fori	wnership m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	v	Amount	(A) (D)	or Pri	ce	Reported Transaction (Instr. 3 and				(11150. 4)
Common Stock 03/17/2					2021			S <sup>(1)</sup>		9,620	9,620 D \$		.84(2)	31,612			D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	xercise (Month/Day/Year) if any (Month/Day/Year) vative			ransaction of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)  Date Exercisable Expiration Date			7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		unt ber		9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		

## **Explanation of Responses:**

- 1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- 2. The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from \$1.80 to \$1.89. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote

## Remarks:

/s/ John Sprague, Attorney-in-

fact

\*\* Signature of Reporting Person Date

03/18/2021

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.